Can I Take Glycine with Retatrutide?

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). That triple mechanism distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP). The glucagon component adds thermogenic caloric expenditure on top of appetite suppression, which likely explains the striking weight-loss figures seen in Phase 2 data.

Phase 2 Clinical Results

In the Phase 2 dose-escalation trial published in the New England Journal of Medicine in 2023 (N=338), retatrutide 12 mg produced a mean body-weight reduction of 24.2% at 48 weeks versus 2.4% with placebo [1]. That figure surpasses the 14.9% mean reduction seen with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961) [2]. Phase 3 trials are ongoing.

Why the Elimination Pathway Matters for Supplement Interactions

Retatrutide is a 39-amino-acid fatty-acid-conjugated peptide. Like other therapeutic peptides, it undergoes proteolytic degradation rather than hepatic cytochrome P450 metabolism. That matters because most supplement-drug interactions occur through CYP3A4, CYP2D6, or P-glycoprotein. Glycine does not meaningfully inhibit or induce any of these transporters, so the usual pharmacokinetic collision that practitioners worry about with, for example, St. John's Wort or berberine simply does not apply here.

What Is Glycine and Why Do People Take It on a GLP-1 Protocol?

Glycine is the smallest and simplest proteinogenic amino acid. The body synthesizes roughly 3 g per day endogenously, but dietary intake and supplemental use can raise plasma glycine substantially. People on GLP-1 and triple-agonist protocols reach for glycine for three distinct reasons: improving sleep quality, supporting collagen synthesis during rapid weight loss, and modest glycemic support.

Glycine for Sleep

A double-blind crossover study by Inagawa et al. (2006, N=11) found that 3 g glycine taken 30 to 60 minutes before bed shortened sleep-onset latency and reduced daytime fatigue versus placebo, with no next-morning sedation [3]. A follow-up polysomnography study by Bannai et al. (2012) confirmed reduced slow-wave sleep latency and subjective sleep quality improvements at the same 3 g dose [4]. Sleep disruption is a documented side effect of GLP-1 receptor agonist titration in some patients, making glycine's mild sleep benefit potentially appealing during dose escalation.

Glycine for Collagen Support During Weight Loss

Rapid weight loss, particularly greater than 15% of body weight, accelerates lean-mass and connective-tissue remodeling. Collagen is roughly 33% glycine by amino acid composition [5]. Supplemental glycine at 3 to 5 g per day is sometimes added to collagen peptide regimens specifically to support skin and connective-tissue turnover during aggressive caloric restriction. No trial has tested this combination specifically in retatrutide users, but the biochemical rationale is straightforward.

Glycine for Glycemic Support

Small controlled trials suggest glycine may modestly increase glucagon-like peptide-1 secretion and improve postprandial glucose disposal. A 2009 crossover study by Gannon et al. (N=10 healthy adults) found that 5 g glycine ingested with a carbohydrate load lowered peak postprandial glucose by roughly 15% compared with carbohydrate alone [6]. That direction of effect overlaps with retatrutide's GLP-1R agonism, which raises a question about additive hypoglycemic risk.

Is There a Pharmacokinetic Interaction Between Glycine and Retatrutide?

No. The two compounds operate through entirely separate elimination systems.

Retatrutide is degraded by tissue and circulating endopeptidases. Its plasma half-life is approximately 6 days, enabling once-weekly dosing. It does not enter the CYP450 system in a clinically meaningful way, and its protein-binding profile is not displaced by amino acids [1].

Glycine is metabolized primarily through the hepatic glycine cleavage system (GCS) and transamination to serine. Neither pathway competes with peptide proteolysis. Renal clearance of glycine is rapid, with plasma levels returning to baseline within 2 to 4 hours of a 3 to 5 g oral dose.

Absorption Timing

Retatrutide is injected subcutaneously once weekly, typically on the same day each week. It achieves peak plasma concentration (Tmax) at approximately 24 hours post-injection [1]. Oral glycine reaches peak plasma at roughly 30 to 45 minutes and is largely cleared within 3 to 4 hours. There is no overlapping absorption window that would cause competition at an intestinal transporter or at plasma protein-binding sites.

What the Natural Medicines Database Says

The Natural Medicines Comprehensive Database (NMCD) rates the glycine-GLP-1 agonist combination as having insufficient evidence to characterize a clinically meaningful interaction, noting no documented case reports of harm [7]. Given that retatrutide is newer than any existing NMCD entry, practitioners should extrapolate from the broader GLP-1 agonist class data while awaiting specific entries.

Pharmacodynamic Considerations: Where Caution Is Warranted

Even without a pharmacokinetic interaction, two pharmacodynamic considerations deserve attention.

Additive Glucose Lowering

Retatrutide lowers fasting and postprandial glucose through both GLP-1R agonism and glucagon-mediated hepatic glucose output regulation. Glycine at 5 g per meal may add a modest incremental reduction in postprandial glucose. For most people on retatrutide monotherapy, hypoglycemia is uncommon because GLP-1R agonists stimulate insulin secretion in a glucose-dependent fashion. The Phase 2 trial reported hypoglycemia in fewer than 2% of participants not co-prescribed a sulfonylurea or insulin [1].

Adding glycine at 3 g for sleep (without a meal) is unlikely to produce clinically significant glucose lowering in isolation. Using glycine at 5 g per meal as a glycemic adjunct introduces a small additive effect. If you are also on metformin, a sulfonylurea, or insulin alongside retatrutide, the combination with glycine at higher doses warrants glucose monitoring.

Overlapping GLP-1 Secretagogue Activity

Glycine's proposed mechanism for improving postprandial glucose involves stimulating endogenous GLP-1 secretion from intestinal L-cells [6]. Retatrutide directly activates GLP-1R regardless of endogenous GLP-1 levels. The practical consequence is that glycine's incremental contribution to GLP-1 pathway activity is likely negligible when the receptor is already fully occupied by exogenous agonist. This is not a dangerous interaction; it simply means glycine's glycemic benefit may be attenuated in people already on retatrutide.

Nausea and GI Tolerability

Glycine is well tolerated at 3 to 5 g doses, with no significant GI adverse effects documented in controlled trials. Retatrutide's most common adverse effects are nausea (up to 46% at 12 mg in Phase 2), vomiting, and diarrhea, particularly during dose escalation [1]. Glycine does not appear to worsen GI motility or gastric emptying. There is no published mechanistic reason to expect glycine to amplify retatrutide-associated nausea, though individual GI sensitivity varies.

Dosing, Timing, and Practical Guidance

The table below summarizes a clinically reasonable approach to glycine use in people prescribed retatrutide. This framework was developed by the HealthRX medical team based on current pharmacokinetic data and published clinical trials. No head-to-head retatrutide-plus-glycine trial exists as of July 2025.

| Glycine Purpose | Suggested Dose | Timing | Monitoring | |---|---|---|---| | Sleep quality | 3 g | 30-60 min before bed | Subjective sleep score; no glucose monitoring needed | | Collagen support | 3-5 g | With or without food | Observe GI tolerance during retatrutide titration | | Glycemic adjunct | 5 g | With main meals | Fasting glucose weekly during dose-escalation phase | | Combined sleep + collagen | 3 g at night | Before bed | Standard retatrutide monitoring applies |

Injection Day Timing

Retatrutide is injected once weekly. Some patients report transient nausea in the 12 to 36 hours following injection, especially early in titration. Starting glycine on injection day introduces a confounding variable if GI side effects occur. A practical option is to begin glycine supplementation on a non-injection day so that any GI response can be attributed correctly.

Dose Escalation Phase Caution

The retatrutide Phase 2 protocol escalated the dose from 0.5 mg to a target of up to 12 mg over 24 weeks [1]. GI adverse effects peak during escalation. Glycine is generally well tolerated, but adding any new supplement during a dose-escalation week makes it harder to interpret tolerance. Waiting until a stable dose is reached before introducing glycine at 5 g per meal is a reasonable, conservative approach.

When to Involve Your Prescriber

Contact your prescriber before adding glycine at doses above 5 g per day if you are also prescribed sulfonylureas or insulin. Routine prescriber notification is good practice for any supplement change while on an investigational agent, since off-label monitoring protocols may vary by clinic.

What the Evidence Says About Glycine Safety in General

Glycine has a well-established general safety profile. The FDA classifies it as GRAS (Generally Recognized as Safe) for use as a direct food ingredient [8]. Doses up to 31 g per day have been used in clinical trials of schizophrenia augmentation without serious adverse events [9]. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not list amino acid supplements as contraindicated with GLP-1 receptor agonists [10].

One edge case deserves mention: very high doses of glycine (above 60 g per day) may produce sedation and GI distress, but these doses far exceed any reasonable supplemental use. Standard sleep and collagen-support doses of 3 to 5 g per day carry no toxicity signal.

Retatrutide's Current Regulatory Status and What It Means for Supplement Guidance

Retatrutide has no FDA-approved package insert as of July 2025. It is available in the United States only through clinical trials or, in some cases, compounding pharmacies operating under state-level prescribing frameworks. The absence of an approved label means there is no official contraindication list to reference.

Implications for Drug Interaction Databases

Standard drug-interaction databases such as Lexicomp, Micromedex, and the Natural Medicines database have limited or no entries for retatrutide specifically. Practitioners should rely on class-level data from approved GLP-1 and dual-agonist agents (liraglutide, semaglutide, tirzepatide) to inform interaction assessments, then apply peptide pharmacokinetic principles to refine the estimate.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm advises clinicians to "use caution when interpreting supplement interaction data for investigational agents and to default to mechanistic pharmacokinetic analysis when database entries are absent" [11].

Monitoring Recommendations During Investigational Use

Because retatrutide is investigational, the monitoring schedule is set by the protocol or prescribing clinician rather than FDA labeling. Adding glycine does not change standard retatrutide monitoring requirements, which typically include:

• Fasting lipid panel at baseline and at 12 weeks
• Fasting glucose and HbA1c at baseline, 12 weeks, and 24 weeks
• Body weight weekly or biweekly
• Adverse-event diary including GI symptoms

If glycine is added for glycemic support at 5 g per meal, adding a postprandial glucose check at 90 minutes post-meal once per week during the first month is a reasonable, low-burden addition.

Who Should Be More Careful

Most adults using retatrutide can add glycine at standard doses (3 to 5 g per day) without meaningful risk. Three specific subgroups warrant closer attention.

People Also Taking Insulin or Sulfonylureas

Retatrutide plus a sulfonylurea or insulin already carries a non-trivial hypoglycemia risk. Glycine at 5 g per meal may add a small incremental glucose-lowering effect. Fingerstick glucose monitoring before meals and at 90-minute post-meal intervals is advisable during the first two weeks of combined use in this group.

People With Renal Impairment

Glycine is renally cleared. People with an eGFR below 30 mL/min/1.73m2 may accumulate glycine if dosing is not adjusted. Retatrutide's renal safety in severe impairment is not yet fully characterized from Phase 2 data. Nephrology co-management is appropriate in this group.

People Using Glycine for High-Dose Neurological Indications

Some off-label glycine protocols for N-methyl-D-aspartate (NMDA) receptor augmentation in psychiatric conditions use 15 to 31 g per day. At those doses, additive sedation during retatrutide-induced sleep disruption recovery could theoretically compound fatigue. This is a very narrow population, and prescriber coordination is strongly recommended.

Summary of Key Points

Glycine and retatrutide do not share a pharmacokinetic interaction pathway. The primary consideration is a modest additive pharmacodynamic effect on postprandial glucose, relevant mainly in people co-prescribed insulin or sulfonylureas. Standard sleep and collagen-support doses of 3 to 5 g per day are unlikely to cause problems for the majority of people using retatrutide.

For most patients, the practical instruction is: take 3 g glycine 30 to 60 minutes before bed on non-injection nights, begin after your first stable retatrutide dose has been achieved, and check your fasting glucose weekly for the first month if you are also on any additional glucose-lowering agent.